Viking Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held on May 24, 2022. As of the record date (March 31, 2022), the Company had 77,373,712 shares of common stock issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Matthew W. Foehr and Charles A. Rowland, Jr. were elected as Class I directors to serve until the 2025 Annual Meeting.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers for the fiscal year ended December 31, 2021.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Matthew W. Foehr received 17,067,685 votes for and 10,728,307 votes withheld.
- Charles A. Rowland, Jr. received 16,320,111 votes for and 11,475,881 votes withheld.
- Ratification of Marcum LLP received 50,705,637 votes for and 431,538 votes against.
- Advisory compensation vote received 25,223,961 votes for and 1,710,747 votes against.
- There were 23,407,373 broker non-votes recorded for the director elections and the compensation advisory vote.